Baker Bros. Advisors INSM Position
Active12-Fund ConvergenceBaker Bros. Advisors trimmed their position in Insmed Incorporated (INSM) in Q4 2025, holding $1.1B worth of shares across 6,592,746 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
INSM is a convergence signal: 12 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Treprostinil Palmitil in 261 days (Dec 31, 2026), making the timing of Baker Bros.'s position particularly relevant.
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Full company profile →Short Interest
5.2%
4.5 days to cover
Baker Bros. Advisors INSM Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 6,592,746 | -110,738 | $1.1B |
| Q3 2025 | Decreased | 6,703,484 | -1,009,416 | $965.4M |
| Q2 2025 | Increased | 7,712,900 | +2,332,274 | $776.2M |
| Q1 2025 | Increased | 5,380,626 | +373,763 | $410.5M |
| Q4 2024 | Increased | 5,006,863 | +590,945 | $345.7M |
| Q3 2024 | Increased | 4,415,918 | +839,880 | $322.4M |
| Q2 2024 | Increased | 3,576,038 | +3,233,038 | $239.6M |
| Q1 2024 | Held | 343,000 | — | $9.3M |
| Q4 2023 | Held | 343,000 | — | $10.6M |
| Q3 2023 | Held | 343,000 | — | $8.7M |
| Q2 2023 | Held | 343,000 | — | $7.2M |
| Q1 2023 | New | 343,000 | +343,000 | $5.8M |
Frequently Asked Questions
Does Baker Bros. Advisors own INSM?
Yes. As of Q4 2025, Baker Bros. Advisors holds 6,592,746 shares of Insmed Incorporated (INSM) valued at $1.1B. This data comes from their SEC 13F filing.
How many hedge funds own INSM?
12 specialist biotech hedge funds currently hold INSM, including RTW Investments, Deep Track Capital, Eventide Asset Management and 8 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy INSM?
Baker Bros. Advisors's position in INSM was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's INSM position increasing or decreasing?
Baker Bros. Advisors trimmed their INSM position in the most recent quarter, reducing by 110,738 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
INSMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →